Therapy Choices and Outcomes in Newly Diagnosed Multiple Sclerosis

Résumé fourni par la source

Background and ObjectivesProspective multinational studies integrating imaging and soluble biomarkers in early multiple sclerosis (MS) are limited. The MultipleMS study compared 2-year clinical, radiologic, and biomarker outcomes across disease-modifying therapies (DMTs) in newly diagnosed MS using harmonized follow-up. MethodsAdults aged 18–50 years with newly diagnosed relapsing or progressive MS and no prior DMT exposure were enrolled at 9 European centers (September 2017–December 2020). Participants were categorized by initial therapy into injectable platform (interferon-beta, glatiramer acetate), oral platform (dimethyl fumarate, teriflunomide), high-efficacy therapies (fingolimod, cladribine, natalizumab, alemtuzumab), B-cell–depleting therapies ([BCDTs]; rituximab, ocrelizumab), or no treatment. Primary outcomes were annualized relapse rate (months 0–24), change in T2 lesion volume (baseline to month 24 [M24]), and serum neurofilament light chain (sNfL) Z-scores at M24. Secondary outcomes included serum glial fibrillary acidic protein (sGFAP) Z-scores, change in Expanded Disability Status Scale (EDSS), and treatment persistence at M24. Analyses used an intention-to-treat approach with adjustment for demographic, baseline disease characteristics, and study center. ResultsOf 509 participants, 455 (89.4%) completed follow-up; the mean age was 33.0 years (interquartile range [IQR] 27.7–40.8), 63.9% were women, the median disease duration was 0.66 years (IQR 0.26–2.14), and the median baseline EDSS was 1.5 (IQR 1.0–2.0). Initial therapies included injectable platform (n = 87, 17.1%), oral platform (n = 152, 29.9%), high efficacy (n = 79, 15.5%), BCDT (n = 101, 19.8%), and untreated (n = 90, 17.7%). Compared with oral platform therapies, BCDT was associated with lower relapse incidence (incidence rate ratio 0.38; 95% CI 0.15–0.92) and greater T2 lesion volume reduction (volume ratio 0.87; 95% CI 0.76–0.99), with similar trends for high-efficacy therapies. Changes in EDSS and sNfL did not differ between groups. sGFAP Z-scores decreased modestly overall, with larger reductions in the oral platform group and relatively higher levels in BCDT and high-efficacy groups. Treatment persistence was higher with BCDT (93.8% vs 72.3%). DiscussionBCDT and high-efficacy therapies exerted greater effects on acute inflammatory than progression-related outcomes, suggesting differential impacts on MS disease processes. Limitations include the observational design and limited follow-up. Trial Registration InformationEudraCT 2017-002634-24, registered on July 06, 2017. First patient enrolled September 29, 2017.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.